1. Home
  2. YAAS vs CMMB Comparison

YAAS vs CMMB Comparison

Compare YAAS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Youxin Technology Ltd

YAAS

Youxin Technology Ltd

SELL

Current Price

$0.70

Market Cap

12.7M

Sector

Technology

ML Signal

SELL

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

SELL

Current Price

$1.22

Market Cap

10.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
YAAS
CMMB
Founded
2018
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7M
10.9M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
YAAS
CMMB
Price
$0.70
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
9.1K
★ 59.0K
Earning Date
08-27-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$28.00
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.92
52 Week High
$4.98
$2.99

Technical Indicators

Market Signals
Indicator
YAAS
CMMB
Relative Strength Index (RSI) 32.98 43.53
Support Level $0.56 $0.99
Resistance Level $1.05 $1.91
Average True Range (ATR) 0.06 0.19
MACD 0.01 0.02
Stochastic Oscillator 0.00 20.74

Price Performance

Historical Comparison
YAAS
CMMB

About YAAS Youxin Technology Ltd

Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: